Compare Davita Inc (DVA) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MakeMyTrip Ltd — how do they compare? Davita Inc trades at $230.28 (market cap $14.92B), while MakeMyTrip Ltd trades at $56.02 (market cap $5.29B). The key difference: Davita Inc is far larger — about 2.8× MakeMyTrip Ltd's market cap, and Davita Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| DVA | MMYT | |
|---|---|---|
Market Cap | $14.92B | $5.29B |
Sector | Health | Technology |
52-Week High | $235.71 | $103.21 |
52-Week Low | $103.87 | $36.30 |
Enterprise Value | $27.47B | $5.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
MakeMyTrip (MMYT) trades at $57.08, down 2.63% today but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with $978M revenue and $95M net income for 2025, though 2026 projections show margin compression. Recent earnings beats and a 73% gross margin highlight operational strength, while technical indicators show bullish moving averages despite recent price weakness.
The stock presents a compelling growth opportunity with strong analyst consensus (73% buy ratings) and consistent earnings outperformance. However, elevated P/E ratio (154.86) and projected margin pressure in 2026 warrant caution. Key risks include travel industry volatility and rising debt-to-asset ratio from 12% to 81% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
